|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2006.07.7230 on December 17 2007 © 2008 American Society of Clinical Oncology. Quality of Life and Survival in the 2 Years After Surgery for Non–Small-Cell Lung Cancer
From the Centre for Health Economics Research and Evaluation (CHERE), University of Technology; Medical Oncology Unit, Sydney Cancer Centre; MBF Health Insurance (formerly CHERE); Department of PET and Nuclear Medicine, and Cardiothoracic Surgical Unit, Royal Prince Alfred Hospital, Sydney, Australia Corresponding author: Patricia Kenny, MPH, Centre for Health Economics Research and Evaluation, University of Technology, Sydney, PO Box 123, Broadway, Sydney, New South Wales 2007, Australia; e-mail: patsy.kenny{at}chere.uts.edu.au Purpose Although surgery for early-stage non–small-cell lung cancer (NSCLC) is known to have a substantial impact on health-related quality of life (HRQOL), there are few published studies about HRQOL in the longer term. This article examines HRQOL and survival in the 2 years after surgery. Patients and Methods Patients with clinical stage I or II NSCLC (n = 173) completed HRQOL questionnaires before surgery, at discharge, 1 month after surgery, and then every 4 months for 2 years. HRQOL was measured with a generic cancer questionnaire (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30) and a lung cancer–specific questionnaire (EORTC QLQ-LC13). Data were analyzed to examine the impact of surgery and any subsequent therapy, and to describe the trajectories of those who remained disease free at 2 years and those with recurrent cancer diagnosed during follow-up. Results Disease recurred within 2 years for 36% of patients and 2-year survival was 65%. Surgery substantially reduced HRQOL across all dimensions except emotional functioning. HRQOL improved in the 2 years after surgery for patients without disease recurrence, although approximately half continued to experience symptoms and functional limitations. For those with recurrence within 2 years, there was some early postoperative recovery in HRQOL, with subsequent deterioration across most dimensions. Conclusion Surgery had a substantial impact on HRQOL, and although many disease-free survivors experienced recovery, some lived with long-term HRQOL impairment. HRQOL generally worsened with disease recurrence. The study results are important for informed decision making and ongoing supportive care for patients with operable NSCLC. Supported by a National Health and Medical Research Council Project Grant No. 991255. Presented in part at the Australian Health Outcomes Conference, September 15-16, 2004, Canberra, Australia, and the annual conference of the International Society for Quality of Life Research, October 16-19, 2004, Hong Kong, China. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:
|
||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|